Chordoid Glioma: A Neoplasm Unique to the Hypothalamus and Anterior Third Ventricle

Martin G. Pomper, Theodore J. Passe, Peter C. Burger, Bernd W. Scheithauer, and Daniel J. Brat

BACKGROUND AND PURPOSE: Chordoid glioma is a new clinicopathologic entity that occurs in the region of the hypothalamus/anterior third ventricle. The aims of this study were to describe the characteristic radiographic features of chordoid glioma, identify specific imaging features that may enable differentiation of chordoid glioma from other suprasellar tumors, and increase neuroradiologists’ awareness of this newly described tumor, facilitating prospective diagnosis.

METHODS: CT scans and/or MR images of six patients with chordoid glioma were reviewed retrospectively to determine whether any characteristic radiographic features would emerge. Reports of the clinical presentation, pathologic findings, and radiographic findings of another six patients were reviewed and included, for a total patient population of 12 (mean age ± SD, 46 ± 13 years).

RESULTS: Imaging features were strikingly similar for all tumors. In each case, the mass was ovoid, was well circumscribed, was located in the region of the hypothalamus/anterior third ventricle, and enhanced uniformly and intensely. Tumors were hyperdense to gray matter on CT scans and were isointense on T1-weighted MR images and slightly hyperintense on long-TR MR images. In two patients, vasogenic edema extended into the optic tracts, and in three, there was hydrocephalus.

CONCLUSION: Chordoid glioma is a recently described unique histopathologic entity that has been added to the World Health Organization glioma classification scheme and must be included in the differential diagnosis of a suprasellar mass. Distinctive imaging features are its location, ovoid shape, hyperdensity on CT scans, and uniform intense contrast enhancement.

Brat et al (1) recently reported a series of low-grade neoplasms arising in the region of the anterior third ventricle/hypothalamus and determined that they represent a unique histopathologic entity. This tumor was named chordoid glioma because of its distinctive histologic appearance, reminiscent of chordoma, and its avid staining with glial fibrillary acidic protein. An evaluation of the imaging studies of patients who were diagnosed with chordoid glioma revealed a striking similarity among all cases. The distinctive imaging features are described herein, and the potential for prospective radiologic diagnosis of chordoid glioma is discussed.

Methods

Patients

Imaging studies (CT and/or MR imaging) of four patients who presented with chordoid glioma after March 1998 and two who presented before that time (Table, patients 1–6) and were included in the initial report of this entity (1) were reviewed retrospectively by two authors (M.G.P., T.J.P.). Reports of the clinical presentations, pathologic findings, and radiographic findings of another six patients were also reviewed and included, for a total patient population of 12 (three male and nine female patients; mean age ± SD, 46 ± 13 years). All diagnoses were determined by histopathologic examination according to published methods at the time of tumor resection (1).

Imaging Protocol

CT (patients 2, 5, 7, and 12) was performed in the axial plane, before and after administration of a bolus IV injection of iohexol (2 mL/kg), with contrast-enhanced coronal reformatting performed for one patient (patient 2). MR imaging was performed on a 1.5-T system in all cases. Although the MR imaging studies were conducted at several institutions, comparable, standard MR parameters were used, with approximate TR as follows: spin-echo T1-weighted sagittal (500/15 [TR/TE/TE]) and double-echo T2-weighted axial (2500/15/100 [TR/TE/TE]). For two patients (patients 3 and 5), a fluid-attenuated inversion recovery sequence (8912/142; inversion...
Patient characteristics and imaging findings

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (y)/Sex</th>
<th>Presentation/Preoperative Diagnosis*</th>
<th>Imaging Findings†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>59/M</td>
<td>Headache/glioma</td>
<td>2.5-cm ovoid, solid, uniformly enhancing hypothalamic/3V‡ mass, central cyst/necrosis</td>
</tr>
<tr>
<td>2</td>
<td>41/F</td>
<td>Headache/meningioma</td>
<td>CT: 3.0-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass</td>
</tr>
<tr>
<td>3</td>
<td>36/M</td>
<td>Memory loss, right homonymous hemianopsia/craniohypophysiotomioma</td>
<td>3.0-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass, surrounding vasogenic edema</td>
</tr>
<tr>
<td>4</td>
<td>40/F</td>
<td>Headache, diplopia, homonymous hemianopsia/meningioma</td>
<td>2.8-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass</td>
</tr>
<tr>
<td>5</td>
<td>35/F</td>
<td>Amenorrhea, psychosis/3V mass</td>
<td>4.0-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass, surrounding vasogenic edema</td>
</tr>
<tr>
<td>6</td>
<td>31/F</td>
<td>Headache, nausea, emesis/pilocytic astrocytoma</td>
<td>3.0-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass</td>
</tr>
<tr>
<td>7</td>
<td>50/F</td>
<td>Lethargy, ataxia, urinary incontinence/meningioma</td>
<td>2.7-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass, hydrocephalus</td>
</tr>
<tr>
<td>8</td>
<td>70/M</td>
<td>Ataxia/suprasellar mass</td>
<td>2.5-cm ovoid, solid/cystic, uniformly enhancing hypothalamic/3V mass</td>
</tr>
<tr>
<td>9</td>
<td>59/F</td>
<td>Obstructive hydrocephalus/ependymoma</td>
<td>1.9-cm ovoid, solid/cystic, uniformly enhancing hypothalamic/3V mass, hydrocephalus</td>
</tr>
<tr>
<td>10</td>
<td>47/F</td>
<td>Obstructive hydrocephalus/3V mass</td>
<td>1.6-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass, hydrocephalus</td>
</tr>
<tr>
<td>11</td>
<td>56/F</td>
<td>Hypothyroidism, diabetes insipidus/suprasellar tumor</td>
<td>1.7-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass</td>
</tr>
<tr>
<td>12</td>
<td>31/F</td>
<td>Hypothyroidism, weight loss/pilocytic astrocytoma</td>
<td>2.8-cm ovoid, solid, uniformly enhancing hypothalamic/3V mass</td>
</tr>
</tbody>
</table>

* Preoperative diagnosis given is as it appeared in the clinical record, verbatim.
† Imaging findings are for MR imaging unless otherwise stated. The greatest dimension of the tumor is given.
‡ Third ventricle.

Results

Imaging features were strikingly similar for all tumors (Table). In each case, the mass was located in the region of the hypothalamus and anterior third ventricle, was ovoid in shape, and was well circumscribed (Fig 1). Mean tumor volume (±SD) was 16.6 ± 13.9 cm³ for patients 1, 3, 5, and 6. Hydrocephalus was noted in three patients (patients 7, 9, and 10) but in none who were available for retrospective analysis. All tumors were separate from the pituitary gland. On CT scans, tumors were hyperdense to gray matter with homogeneous enhancement (Fig 2). Tumors were isointense on T1-weighted MR images and isointense to slightly hyperintense on long-TR MR images, and all enhanced essentially uniformly (Fig 3). The tumors of patients 1, 8, and 9 contained a central cystic or necrotic area (Fig 4), although the corresponding biopsy specimens did not indicate the presence of necrosis. In two of the patients available for review (patients 3 and 5), T2 bright signal due to vasogenic edema extended into the optic tracts (Fig 3).

Detailed pathologic results have been described elsewhere but generally revealed clusters and cords of oval-to-polygonal epithelioid cells with abundant eosinophilic cytoplasm (Fig 5) (1). No anaplastic features were identified, and there was no appreciable infiltration of the surrounding brain parenchyma. The overall cytologic features were consistent with those of a low-grade neoplasm.
Fig 1. Representative appearance of chordoid glioma on MR images. Note the location of the mass in the hypothalamus/third ventricle region, dense enhancement, and greatest dimension in the superoinferior orientation.

A. Sagittal contrast-enhanced spin-echo MR image (500/15) of Patient 1, a 59-year-old man. Note hypothalamic involvement (arrows).

B. Coronal contrast-enhanced spin-echo MR image (500/15) of Patient 1, a 59-year-old man. Note hypothalamic involvement (arrows).

C. Unenhanced sagittal spin-echo MR image (500/14) of Patient 3, a 36-year-old man. Arrows demarcate the suprasellar mass.

D. Contrast-enhanced sagittal spin-echo MR image (500/14) of Patient 3, a 36-year-old man. Note the posterior displacement of the infundibulum (arrow).

Fig 2. CT scans of Patient 2, a 41-year-old woman with chordoid glioma.

A. Unenhanced axial CT scan reveals a hyperdense mass (arrow) that enhances uniformly in the suprasellar region.

B. Contrast-enhanced axial CT scan reveals a hyperdense mass that enhances uniformly (arrow) in the suprasellar region.

Discussion

During the past decade, a series of histopathologically perplexing neoplasms, each arising in the region of the hypothalamus and anterior third ventricle, were seen in consultation at our institution and at the Mayo Clinic. These neoplasms had the histologic appearance of cords and clusters of epithelioid cells within a mucinous background along with a low-grade lymphoplasmacytic infiltrate, reminiscent of a chordoma or chordoid meningioma (Fig 5). Unlike chordomas or chordoid meningiomas, however, which are not glial in origin, these tumors all stained avidly for the glial cell marker glial fibrillary acidic protein. This new tumor did not conform to any existing glioma histopathologic classification system, leading Brat et al (1) to propose that chordoid glioma was a separate pathologic entity. Since that original report, four new cases have come to our attention and at least six other cases have appeared in the literature (2, 3). Interestingly, in 1995, Wanschitz et al (4) reported a case of a peculiar suprasellar meningioma that exhibited atypical expression of glial fibrillary acidic protein and probably represents another example of a chordoid glioma. Chordoid glioma has recently been added to the World Health Organization glioma classification scheme (5). Although the incidence of chordoid glioma cannot yet
be evaluated because of its recent description, it seems to be an uncommon tumor.

The cell of origin for chordoid glioma remains unknown. A recent case report indicates that the neoplasm arises from the subependymal tissue (6). That same report noted that despite the glial nature of these lesions, the presence of histiocytes and giant cells suggests the presence of other cellular types with unknown roles and significance. Another strong possibility is that the tumors arise from the hypothalamus. That is supported in that most lesions are tightly adherent to the hypothalamus at surgery, resulting in a difficult resection, although the tumor is otherwise well circumscribed.

Patients presented clinically in a variety of fashions, generally related to the local mass effect of the tumor (eg, headaches, obstructive hydrocephalus, homonymous hemianopsia, and hypothalamic dysfunction) (Table). The current treatment of choice for chordoid glioma is surgical resection. As mentioned above, even though the tumor is otherwise well margined, surgeons have frequently reported that the mass is tightly adherent to the hypothalamus, resulting in either subtotal resection or hypothalamic symptoms (eg, diabetes insipidus resulting from aggressive removal). Tumors that have undergone subtotal resection tend to recur. Chemotherapy and radiation therapy have been unsuccessful in the few cases in which these modes of therapy have been applied. Despite that chordoid glioma is a pathologically low-grade tumor, prognosis in the limited number of cases has been relatively poor, primarily because of its location and the difficulty in obtaining complete surgical resection without the patient’s suffering severe hypothalamic symptoms.

Because the local anatomy is complex and composed of tissues that may develop into tumors, such as the cranial nerves, the cavernous sinuses, the pituitary gland, and the skull base, 80% of suprasellar lesions are tumors (7, 8). That there are many possible tumor types is a diagnostic dilemma for the radiologist who discovers a suprasellar mass. Pituitary macroadenomas, craniopharyngiomas, meningiomas, metastases, optic and hypothalamic pilocytic astrocytomas, and aneurysms account for more than 75% of these lesions. Other less common entities include Rathke cleft cysts, hamartomas of the tuber cinereum, and granulomatous diseases such as sarcoid, tuberculosis, and eosinophilic granuloma. Tumors of the third ventricle constitute an uncommon subset of suprasellar masses. These tumors have been addressed previ-
Chordoid glioma is a recently described, unique pathologic entity that has been added to the World Health Organization glioma classification scheme and must be considered in the differential diagnosis of third ventricular/hypothalamic tumors. Distinctive imaging characteristics are its consistent location, ovoid shape, hyperdensity on CT scans, and uniform intense contrast enhancement. When present, mass effect causing vasogenic edema tends to be bilaterally symmetrical and may involve the optic tracts. When confronted with a suprasellar mass with these imaging features, the neuroradiologist must consider chordoid glioma in the differential diagnosis.

**Conclusion**

Chordoid glioma is a recently described, unique pathologic entity that has been added to the World Health Organization glioma classification scheme and must be considered in the differential diagnosis of third ventricular/hypothalamic tumors. Distinctive imaging characteristics are its consistent location, ovoid shape, hyperdensity on CT scans, and uniform intense contrast enhancement. When present, mass effect causing vasogenic edema tends to be bilaterally symmetrical and may involve the optic tracts. When confronted with a suprasellar mass with these imaging features, the neuroradiologist must consider chordoid glioma in the differential diagnosis.

**References**


